Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
61-75 of 4506 results
GSK enters into drug discovery collaboration with Exscientia
By PBR Staff Writer
British drugmaker GlaxoSmithKline (GSK) has established a drug discovery collaboration with Frontier IP portfolio firm Exscientia.
Drug Research > Drug Discovery & Development > News
CytomX advances CD71-targeting probody drug conjugate into GLP toxicology studies
CytomX Therapeutics has advanced CX-2029, a probody drug conjugate (PDC) targeting CD71 and being developed in collaboration with AbbVie, into GLP toxicology studies, an important step on the path to filing an Investigational New Drug (IND) application next year.
Drug Research > Drug Discovery & Development > News
LifeArc, Dstl & CDRD partner to identify antibacterial drug targets
By PBR Staff Writer
UK-based LifeArc and Defence Science and Technology Laboratory (Dstl) will collaborate with Canada’s The Centre for Drug Research and Development (CDRD) to identify antibacterial drug targets.
Drug Research > Drug Discovery & Development > News
Arix Bioscience buys stake in Mitoconix Bio
Healthcare and life science firm Arix Bioscience has acquired a stake in Mitoconix Bio as part of an oversubscribed $20m Series A financing round.
Drug Research > Drug Discovery & Development > News
FDA accepts for filing Icon’s NDA for Dexycu drug therapy
The US Food and Drug Administration (FDA) has accepted for filing Icon Bioscience (IBI), recently submitted new drug application (NDA) for Dexycu (IBI-10090), a novel drug for treating inflammation associated with cataract surgery.
Drug Research > Drug Discovery & Development > News
Pfizer gets CRL on Epogen biosimilar from FDA
By PBR Staff Writer
The United States Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Pfizer in connection with its biosimilar candidate to Amgen’s anemia drug Epogen (epoetin alfa).
Drug Research > Drug Discovery & Development > News
Cancer frim Repare Therapeutics announces $68m Series A financing
Repare Therapeutics has secured $68m in a Series A financing round which it will use to advance its platform and pipeline of novel medicines that target genetically defined weaknesses of cancers.
Drug Research > Drug Discovery & Development > News
Rubius Therapeutics raises $120m to advance red blood cell technology
Rubius Therapeutics, which is developing red-cell therapeutics (RCTs) as a new class of medicines to address a range of indications, has raised $120m in a highly oversubscribed private financing.
Drug Research > Drug Discovery & Development > News
EIB supports development of BiondVax’s universal flu vaccine candidate
BiondVax Pharmaceuticals, which is developing a universal vaccine for all strains of influenza, has signed an agreement with the European Investment Bank (EIB) for a €20m loan.
Drug Research > Drug Discovery & Development > News
Axovant’s dementia drug granted FDA fast track designation
Axovant Sciences’ investigational drug nelotanserin has secured fast track designation from the US Food and Drug Administration (FDA) for the treatment of visual hallucinations disorder in dementia with Lewy bodies (DLB).
Drug Research > Drug Discovery & Development > News
Accenture, 1QBit work with Biogen to apply quantum computing to speed up drug discovery
Accenture and 1QBit have partnered with Biogen to develop a quantum-enabled molecular comparison application that could considerably improve advanced molecular design to accelerate drug discovery for complex neurological conditions like multiple sclerosis, Alzheimer’s, Lou Gehrig’s Disease and Parkinson’s.
Drug Research > Drug Discovery & Development > News
Domainex, Imperial College London expand cardiac therapy collaboration
Domainex has extended its partnership with Imperial College London to discover novel therapies that reduce heart muscle damage during heart attacks.
Drug Research > Drug Discovery & Development > News
Omeros’ OMS721 kidney drug gets FDA breakthrough therapy status
By PBR Staff Writer
Omeros’ MASP-2 inhibitor OMS721 has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for the treatment of Immunoglobulin A (IgA) nephropathy.
Drug Research > Drug Discovery & Development > News
Selexis, TeneoBio sign deal to advance development of UniAbs targeting cancer
Selexis and TeneoBio have signed a service agreement to jointly advance the development of a new class of biologics, Human Heavy-Chain Antibodies (UniAbs) targeting cancer.
Drug Research > Drug Discovery & Development > News
Numerate, Takeda partner to generate clinical candidates using AI-driven drug discovery
Numerate has entered into a multi-year agreement with Takeda Pharmaceutical under which it will identify and deliver multiple clinical candidates by applying artificial intelligence (AI) at cloud scale.
Drug Research > Drug Discovery & Development > News
61-75 of 4506 results